Skip to content

PMI CONSTRUCTION: what changed

BE 0865.187.540NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2023 and 2024

Net result for the year
-€3,788
2023 · €2,016-€5,804
Equity
€7,199
2023 · €10,987-€3,788
Cash
€1,291
2023 · €2,233-€942
Balance sheet total
€11,405
2023 · €15,619-€4,214

Largest movements

2023 to 2024
Assets
  • Receivables within one year -€1,686

    down €1,686 (-73.7%), from €2,287 to €601

    of which Trade receivables: -€937

  • Stocks and contracts -€1,585

    down €1,585 (-14.3%), from €11,099 to €9,514

  • Cash -€942

    down €942 (-42.2%), from €2,233 to €1,291

    mainly Net result for the year (-€3,788) and Other debts (-€214)

Equity and liabilities
  • Profit (loss) carried forward -€3,788

    down €3,788 (-76.2%), from -€4,971 to -€8,760

  • Other debts -€214

    down €214 (-5.0%), from €4,266 to €4,052

  • Trade debts -€211

    down €211 (-57.8%), from €365 to €154

Income statement
  • Gross operating margin -€5,186

    down €5,186, from €2,465 to -€2,721

  • Turnover -€5,106

    down €5,106 (-16.4%), from €31,181 to €26,075

  • Taxes +€635

    first reported in 2024, at €635

  • Other operating charges -€323

    no longer reported in 2024; in 2023 it stood at €323

Change in the result, 2023 to 2024

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2023 €2,016
Gross operating margin -€5,186
Other operating charges +€323
Financial income -€37
Financial charges -€270
Taxes -€635
Result 2024 -€3,788
raises the resultlowers the result

Derived cash bridge

cash 2023 to 2024

The bridge is derived from the 2023 and 2024 balance sheets and the 2024 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations -€942
Investment €0
Financing €0
Cash 2023 €2,233
Net result for the year -€3,788
Stocks and contracts +€1,585
Receivables within one year +€1,686
Trade debts -€211
Other debts -€214
Cash 2024 €1,291
brings cash intakes cash out
Every line side by side 38 lines
Line Code 2023 2024 Change %
Total assets 20/58 €15,619 €11,405 -€4,214 -27.0%
Current assets 29/58 €15,619 €11,405 -€4,214 -27.0%
Stocks and contracts in progress 3 €11,099 €9,514 -€1,585 -14.3%
Stocks 30/36 €11,099 €9,514 -€1,585 -14.3%
Amounts receivable within one year 40/41 €2,287 €601 -€1,686 -73.7%
Trade receivables 40 €1,493 €556 -€937 -62.7%
Other amounts receivable 41 €794 €45 -€749 -94.4%
Cash at bank and in hand 54/58 €2,233 €1,291 -€942 -42.2%
Total equity and liabilities 10/49 €15,619 €11,405 -€4,214 -27.0%
Equity 10/15 €10,987 €7,199 -€3,788 -34.5%
Contributions 10/11 €6,200 €6,200 = 0.0%
Capital 10 €6,200 €6,200 = 0.0%
Issued capital 100 €18,600 €18,600 = 0.0%
Uncalled capital 101 €12,400 €12,400 = 0.0%
Reserves 13 €9,759 €9,759 = 0.0%
Non-distributable reserves 130/1 €1,860 €1,860 = 0.0%
Legal reserve 130 €1,860 €1,860 = 0.0%
Distributable reserves 133 €7,899 €7,899 = 0.0%
Profit (loss) carried forward 14 -€4,971 -€8,760 -€3,788 -76.2%
Amounts payable 17/49 €4,632 €4,207 -€425 -9.2%
Amounts payable within one year 42/48 €4,632 €4,207 -€425 -9.2%
Trade debts 44 €365 €154 -€211 -57.8%
Suppliers 440/4 €365 €154 -€211 -57.8%
Other amounts payable 47/48 €4,266 €4,052 -€214 -5.0%
Turnover 70 €31,181 €26,075 -€5,106 -16.4%
Goods, raw materials, services and sundry goods 60/61 €28,715 €28,796 +€80 +0.3%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €0 - =
Other operating charges 640/8 €323 - -€323
Gross operating margin 9900 €2,465 -€2,721 -€5,186
Operating profit (loss) 9901 €2,142 -€2,721 -€4,863
Financial income 75/76B €37 - -€37
Recurring financial income 75 €37 - -€37
Financial charges 65/66B €163 €433 +€270 +166%
Recurring financial charges 65 €163 €433 +€270 +166%
Profit (loss) for the period before taxes 9903 €2,016 -€3,154 -€5,170
Income taxes 67/77 - €635 +€635
Profit (loss) for the period 9904 €2,016 -€3,788 -€5,804
Profit (loss) for the period to be appropriated 9905 €2,016 -€3,788 -€5,804

Value

latest balance sheet 31-12-2024 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€7,199 to €7,199

Midpoint €7,199 · adjusted equity only

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €7,199
Indication €7,199

Adjusted equity

balance sheet 31-12-2024
Equity (10/15)
€7,199
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€7,199

Capitalised earnings

net result for the year (9904)
2024
-€3,788
2023
€2,016
2022
-€1,122
excluding non-recurring income and charges
-€919
2020
-€1,631
2019
€108
Average result, excluding non-recurring income and charges
-€897
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
not meaningful, as the average result is zero or negative

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2023 and 31 December 2024. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 17 November 2026 via checked.be.